Replies to post #643 on Biotech Values

[DewDiligence]

From the same OXGN patent:

>>
[0141] Topical gels and solutions were developed for use as topical formulation suitable for the topical delivery of CA4P to the surface of the eye. Topical solutions (1, 3, and 10%) were directly prepared in 0.9% NaCl (Aguettant, Lyon, France) and sterilized with 0.2 um filter (pH 6.4 to 8.5, osmolarity 290 to 459 mosmol/kg H.sub.2O. Low viscosity topical gels (1,3,and 10%) were prepared in 0.5% carboxymethylcellulose (Sigma Aldrich Chimie, St. Quentin Fallavier Cedex, France) with 0.9% NaCl.
<<

--
isolution: A little birdie tells me that you may be familiar with this work :-)

Are you aware of any conflicting or overlapping patents held by AVE, AZN, or other companies in the use of VTA’s in eye diseases? T.i.a.